



# SPRING 2024

## INVESTOR CONFERENCE

MAY 30, 2024 | [lythampartners.com/spring2024](https://lythampartners.com/spring2024)



## VIRTUAL CONNECTIONS. REAL VALUE.

The Lytham Partners Investor Select Conference is an exclusive event featuring curated fireside chats hosted by industry leading analysts. Specialty companies are selected for participation and span various industries including healthcare, consumer, agriculture, technology, industrials, fintech and energy/cleantech.

### ABOUT LYTHAM PARTNERS

Lytham Partners is one of the country's leading investor relations firms. With more than two decades of Corporate Access experience, we have built one of the industry's most diverse and effective platforms for connecting small cap companies with high quality and focused institutional investors.

### ABOUT OUR CONFERENCES

The mission of the Lytham Partners Investor Conference Series is to create value for small cap companies through virtual connections with high-quality institutional investors. Our conference series has featured more than 300 companies from various industries including healthcare & pharma, consumer, technology, industrials & special situations, clean tech, and financial services.

### CONNECT WITH US

We are excited to connect with our audience and share this virtual event online. Follow Lytham Partners IR on LinkedIn and [click here](#) to RSVP to our event page to stay updated on the latest conference news.



#lythamspring2024



## PARTICIPATING COMPANIES

This list has been updated as of May 8, 2024. Participation subject to change.

### BASIC MATERIALS

Ariane Phosphate (OTCQX: DRRSF / TSXV: DAN)  
Basic Materials: Battery and Ag. Inputs | Market Cap: \$34M

Criterion Energy (TSXV: CEQ)  
Energy: SE Asia O&G | Market Cap: \$10M

Greenfire Resources (NYSE: GFR / TSX: GFR)  
Basic Materials: Canadian Oil Sands | Market Cap: \$400M

### CONSUMER

ChromaDex Corporation (NASDAQ: CDXC)  
Consumer: Healthy Aging | Market Cap: \$255M

Else Nutrition Holdings Inc. (OTCQX: BABYF / TSXV: BABY)  
Consumer: Baby Food | Market Cap: \$26M

Flow Beverage Corp. (OTCQX: FLWBF / TSX: FLOW)  
Consumer: Water | Market Cap: \$13M

Lincoln Educational Services (NASDAQ: LINC)  
Consumer: Education Services | Market Cap: \$315M

### COMM. PHARMA

Aytu BioPharma, Inc. (NASDAQ: AYTU)  
Comm. Pharma: ADHD/Pediatrics | Market Cap: \$160M

Jaguar Health, Inc. (NASDAQ: JAGX)  
Comm. Pharma: GI | Market Cap: \$47M

### DEV. PHARMA

Cadrenal Therapeutics (NASDAQ: CVKD)  
Dev. Pharma: Blood Thinner | Market Cap: \$7M

Dyadic International, Inc. (NASDAQ: DYAI)  
Dev. Pharma: Protein Production | Market Cap: \$45M

Kairos Pharma (PRIVATE)  
Dev. Pharma: Oncology

Kiora Pharma (NASDAQ: KPRX)  
Dev. Pharma: Retinal Disease | Market Cap: \$32M

Reviva Pharmaceuticals (NASDAQ: RVPH)  
Dev. Pharma: CNS | Market Cap: \$83M

Shuttle Pharmaceuticals, Inc. (NASDAQ: SHPH)  
Dev. Pharma: Oncology | Market Cap: \$7M

Unicycive Therapeutics, Inc. (NASDAQ: UNCY)  
Dev. Pharma: Kidney Disease | Market Cap: \$35M

### MEDICAL DEVICE

Beyond Air, Inc. (NASDAQ: XAIR)  
Medical Device: Nitric Oxide | Market Cap: \$53M

Delcath Systems (NASDAQ: DCTH)  
Medical Device: Oncology | Market Cap: \$100M

Modular Medical, Inc. (NASDAQ: MODD)  
Medical Device: Insulin Pump | Market Cap: \$47M

NeurAxis (NYSE American: NRXS)  
Medical Device: Irritable Bowel | Market Cap: \$20M

Zomedica (NYSE American: ZOM)  
Medical Device: Animal Health | Market Cap: \$128M

### HEALTHCARE

ImmuCell Corporation (NASDAQ: ICCG)  
Healthcare: Animal Health | Market Cap: \$40M

INVO Bioscience (NASDAQ: INVO)  
Healthcare: Fertility | Market Cap: \$4M

Reliq Health Technologies (OTC: RQHTF / TSXV: RHT)  
Healthcare: Technology Services | Market Cap: \$35M

Scientific Industries, Inc. (OTCQB: SCND)  
Healthcare: Life Sciences | Market Cap: \$18M

Syra Health Corp. (NASDAQ: SYRA)  
Healthcare: Behavioral Technology | Market Cap: \$15M

Trinity Biotech plc (NASDAQ: TRIB)  
Healthcare: Diagnostics | Market Cap: \$18M

### INDUSTRIALS

Arq, Inc. (NASDAQ: ARQ)  
Industrials: Pollution & Treatment Controls | Market Cap: \$210M

Civeo Corp. (NYSE: CVEO)  
Industrials: Oil & Gas Services | Market Cap: \$380M

LiqTech International, Inc. (NASDAQ: LIQT)  
Industrials: Filtration | Market Cap: \$15M

S&W Seed Company (NASDAQ: SANW)  
Industrials: Agriculture | Market Cap: \$20M

SenesTech, Inc. (NASDAQ: SNES)  
Industrials: Rodent Control | Market Cap: \$5M

### TECHNOLOGY

Bitcoin Well, Inc. (OTCQB: BCNWF / TSXV: BTCW)  
Technology: Crypto | Market Cap: \$21M

Coda Octopus Group (NASDAQ: CODA)  
Technology: Underwater Optics | Market Cap: \$77M

The Glimpse Group (NASDAQ: VRAR)  
Technology: VR/AR Software | Market Cap: \$20M

GSE Systems, Inc. (NASDAQ: GVP)  
Technology: Nuclear | Market Cap: \$10M

Lucas GC Limited (NASDAQ: LGCL)  
Technology: Staffing Services | Market Cap: \$200M

Mogo Inc. (NASDAQ: MOGO / TSX: MOGO)  
Technology: FinTech | Market Cap: \$45M

Peraso Inc. (NASDAQ: PRSO)  
Technology: Semiconductors | Market Cap: \$4M

Precision Optics Corporation (NASDAQ: POCI)  
Technology: Optics | Market Cap: \$35M

Sabio Holdings Inc. (OTCQX: SABOF / TSXV: SBIO)  
Technology: Advertising | Market Cap: \$12M

SOBR Safe, Inc. (NASDAQ: SOBR)  
Technology: Alcohol Detection | Market Cap: \$6M

Spire Global (NYSE: SPIR)  
Technology: Satellite | Market Cap: \$237M

Zoomd Technologies (OTC: ZMDTF / TSXV: ZOMD)  
Technology: Advertising | Market Cap: \$6M



# WEBCAST SCHEDULE

All times are in Eastern Standard Time. Schedule subject to change.

	TRACK 1	TRACK 2	TRACK 3	TRACK 4	TRACK 5: INDUSTRY PANELS
8:30AM-9:15AM	Keynote Panel: Presentation on CBOE: What you Need to Know About the New Equity Listing Alternative to NASDAQ and NYSE with Erik Sloane of CBOE & Joseph Lucosky of Lucosky Brookman				
9:15AM-9:30AM					T+1 Settlement is Here - What Market Participants Need to Know Robert Charron, Ellenoff Grossman & Schole LLP
9:30AM-10:00AM	LiqTech International (NASDAQ: LIQT)	Lucas GC Limited (NASDAQ: LGCL)	NeurAxis (NYSE American: NRXS)	Unicycive Therapeutics (NASDAQ: UNCY)	
10:00AM-10:15AM					Potential Impact of SEC's Interpretation of "Dealer" Tag for Companies and Investors Marc Indeglia, Glaser Weil Fink Howard Jordan & Shapiro LLP
10:15AM-10:45AM	Civeo (NYSE: CVEO)	Spire Global (NYSE: SPIR)	Zomedica (NYSE American: ZOM)	Reviva Pharmaceuticals (NASDAQ: RVPH)	
10:45AM-11:00AM					Investing in a Higher Interest Environment: Ins and Outs of the Micro/SmallCap Marketplace Doug Weiss, DSW Investments   Yale Bock, Y H & C Investments   Randy Watsek, Raymond James
11:00AM-11:30AM	S&W Seed Company (NASDAQ: SANW)	The Glimpse Group (NASDAQ: VRAR)	Delcath Systems (NASDAQ: DCTH)	Shuttle Pharma (NASDAQ: SHPH)	
11:30AM-11:45AM					Analyst Insights into the Agriculture Sector Ben Klieve, Lake Street Capital Markets
11:45AM-12:15PM	SenesTech (NASDAQ: SNES)	Peraso Inc. (NASDAQ: PRSO)	Reliq Health Technologies (OTC: RQHTF / TSXV: RHT)	Dyadic International (NASDAQ: DYAI)	
12:15PM-12:30PM					Analyst Insights into the Environmental Industrials Sector Gerry Sweeney, Roth Capital
12:30PM-1:00PM	Arianne Phosphate (OTCQX: DRRSF / TSXV: DAN)	Coda Octopus Group (NASDAQ: CODA)	Syra Health Corp. (NASDAQ: SYRA)	Cadrenal Therapeutics (NASDAQ: CVKD)	
1:00PM-1:15PM					Feeding the Planet – A VC's View on Sustainable Solutions in a Lower Carbon Future Dan Gluck, GroundForce Capital
1:15PM-1:45PM	Greenfire Resources (NYSE: GFR / TSX: GFR)	Precision Optics Corp. (NASDAQ: POCL)	Flow Beverage (OTCQX: FLWBF / TSX: FLOW)	AYTU Biopharma (NASDAQ: AYTU)	
1:45PM-2:00PM					Small Cap Investor Insights Ryan Ruggaard, Ruggaard & Assoc.   Chris Abbott, 1035 Capital   Matt Shelfer, Investment Strategies Fund
2:00PM-2:30PM	ChromaDex Corp. (NASDAQ: CDXC)	Bitcoin Well (OTCQB: BCNWF / TSXV: BTCW)	Lincoln Educational Services (NASDAQ: LINC)	Jaguar Health (NASDAQ: JAGX)	
2:30PM-2:45PM					GPS for Alpha: Investing on a Global Basis Jake Barfield, Asheville Capital Management Doug Weiss, DSW Investments
2:45PM-3:15PM	SOBR Safe, Inc. (NASDAQ: SOBR)	Mogo, Inc. (NASDAQ: MOGO / TSX: MOGO)	Scientific Industries, Inc. (OTCQB: SCND)	Kiora Pharma (NASDAQ: KPRX)	
3:30PM-4:00PM	Beyond Air, Inc. (NASDAQ: XAIR)	Sabio Holdings Inc. (OTCQX: SABOF / TSXV: SBIO)	Modular Medical, Inc. (NASDAQ: MODD)	Criterion Energy (TSXV: CEQ)	
4:15PM-4:45PM	Kairos Pharma (PRIVATE)				

The following companies will be participating in 1x1 meetings only	Arq, Inc. (NASDAQ: ARQ)	INVO Bioscience (NASDAQ: INVO)	Trinity Biotech (NASDAQ: TRIB)	ImmuCell Corporation (NASDAQ: ICCG)
	Else Nutrition Holdings (OTCQX: BABYF / TSXV: BABY)	Zoomd Technologies (OTC: ZMDTF / TSXV: ZOMD)	GSE Systems (NASDAQ: GVP)	



## CONFERENCE CONTRIBUTORS

Thank you to our contributors!

### KEYNOTE



### CONTRIBUTING ANALYSTS



## COMPANY PROFILES

Market Cap data (\$USD) updated as of 4.29.24

### **ARIANNE PHOSPHATE INC. (OTCQX: DRRSF / TSXV: DAN)**

**Basic Materials: Battery and Ag. Inputs | Market Cap: \$34M**

Arienne Phosphate Inc. (listed TSX-V: DAN and OTC: DRRSF) is a Canadian company dedicated to developing its Lac a Paul mining project, one of the most prolific phosphate projects in the world. Arienne Phosphate's mission is to produce high-quality apatite (phosphate) through an environmentally friendly phosphate mine for use in a wide range of applications for the betterment of society. Through renewable hydroelectricity, we strive to diminish our production of greenhouse gases to achieve GHG neutrality. We are moving the project towards development to the betterment of all stakeholders and investors to unlock the significant social and economic benefits to the region.

### **ARQ, INC. (NASDAQ: ARQ)**

**Industrials: Pollution & Treatment Controls | Market Cap: \$210M**

Arq (NASDAQ: ARQ) is a diversified, environmental technology company with products that enable a cleaner and safer planet while actively reducing our environmental impact. As the only vertically integrated producer of activated carbon products in North America, we deliver a reliable domestic supply of innovative, hard-to-source, high-demand products. We apply our extensive expertise to develop groundbreaking solutions to remove harmful chemicals and pollutants from water, land and air.

### **AYTU BIOPHARMA, INC. (NASDAQ: AYTU)**

**Comm. Pharma: ADHD/Pediatrics | Market Cap: \$160M**

Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit [aytubio.com](http://aytubio.com).

### **BEYOND AIR, INC. (NASDAQ: XAIR)**

**Medical Device: Nitric Oxide | Market Cap: \$53M**

Beyond Air, Inc., a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.)

### **BITCOIN WELL, INC. (OTCQB: BCNWF / TSXV: BTCW)**

**Technology: Crypto | Market Cap: \$21M**

Bitcoin Well is on a mission to enable independence. We do this by giving our customers an ecosystem of products and services that have the same convenience as modern banking, but give the full benefits of bitcoin. We have 2 business units: 1. Bitcoin ATMs - a network of 200 across Canada 2. Bitcoin Portal - a web app live in Canada and the USA that offers safe, non custodial ways to buy bitcoin.

### **CADRENAL THERAPEUTICS (NASDAQ: CVKD)**

**Dev. Pharma: Blood Thinner | Market Cap: \$7M**

Cadrenal Therapeutics is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions. Tecarfarin has orphan drug and fast track designations from the FDA for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). Cadrenal is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients with left ventricular assist devices (LVADs) and those with thrombotic antiphospholipid syndrome (APS). Tecarfarin is specifically designed to leverage a different metabolism pathway than the oldest and most commonly prescribed Vitamin K Antagonist (warfarin). Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: [www.cadrenal.com](http://www.cadrenal.com).

### **CHROMADEx CORPORATION (NASDAQ: CDXC)**

**Consumer: Healthy Aging | Market Cap: \$255M**

ChromaDex is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, NIAGEN® (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

### **CIVEO CORPORATION (NYSE: CVEO)**

**Industrials: Oil & Gas Services | Market Cap: \$380M**

Civeo Corporation is a leading provider of hospitality services with prominent market positions in the Canadian oil sands and the Australian natural resource regions. Civeo offers comprehensive solutions for lodging hundreds or thousands of workers with its long-term and temporary accommodations and provides food services, housekeeping, facility management, laundry, water and wastewater treatment, power generation, communications systems, security and logistics services. Civeo currently operates a total of 24 lodges and villages in Canada, Australia and the U.S., with an aggregate of approximately 26,000 rooms.

## COMPANY PROFILES

Market Cap data (\$USD) updated as of 4.29.24

### **CODA OCTOPUS GROUP, INC. (NASDAQ: CODA)**

**Technology: Underwater Optics | Market Cap: \$77M**

Coda Octopus Group, founded in 1994, is an established supplier to the Underwater/Subsea market. It supplies a range of hardware and software solutions to this market which includes key proprietary real time 4D/5D/6D imaging sonars, marketed under the name Echoscope® and Echoscope PIPE® addressing the underwater imaging sensor market along with new generation diving technology, Diver Augmented Vision Display (DAVD) system. The Company's Echoscope PIPE® sonar generates real-time 3D/4D/5D images of moving objects underwater including in zero visibility water conditions. The Echoscope® technology is used globally for numerous applications in both the commercial offshore market and defense underwater markets. Applications for the Echoscope® technology include complex mapping underwater, subsea intervention, subsea asset placements, salvage and recovery, search and rescue, offshore renewables cable installations and surveys, marine construction, subsea infrastructure installation, mining applications, robotics (3D Perception and Depth), breakwater construction and monitoring, decommissioning, diving applications and port and harbor security. The recently launched new generation of diving technology, DAVD, has the potential to change the way global diving operations are performed (both in the Defense and Commercial space) because it is a fully integrated singular system for topside control and fully connected diver HUD system, allowing both the topside and diver to share a range of critical information and visualize the same underwater scene. Furthermore, the DAVD integrates the Company's sonar technology, which allows dive operations to be performed in zero visibility conditions, a common problem that besets these operations. The Company also includes two discrete Defense engineering businesses Coda Octopus Martech Ltd (UK based) and Coda Octopus Colmek, Inc. (US based) whose primary business model is to supply sub-assemblies into broader mission critical programs in the capacity of sub-contractors to the Prime Defense Contractors. Their scope of supply under these programs typically includes concept, design, prototype, manufacturing, and post-sale support. This gives them the opportunity to have repeat orders for these sub-assemblies through the life of these programs.

### **CRITERIUM ENERGY (TSXV: CEQ)**

**Energy: SE Asia O&G | Market Cap: \$10M**

Criterion Energy Ltd. (TSXV: CEQ) is an upstream energy company focused on the consolidation and sustainable development of assets in Southeast Asia that can deliver scalable growth and cash flow generation. This region is expected to house a population approaching 800 million people within the next 25 years, driving world-leading economic growth and record energy demand. Criterion intends to contribute responsible, safe and secure sources of energy to help meet this demand, while maximizing total shareholder return by executing across three strategic pillars that include (1) fostering a successful and sustainable reputation; (2) leveraging innovation and technology arbitrage; and (3) achieving operational excellence with an unwavering commitment to safety.

### **DEL CATH SYSTEMS (NASDAQ: DCTH)**

**Medical Device: Oncology | Market Cap: \$100M**

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT™ (melphalan for Injection/Hepatic Delivery System), approved for use in the United States by the Food and Drug Administration, and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), designated under the medical device regulation for use in Europe and the United Kingdom, are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. For more information regarding HEPZATO KIT and its use, including Important Safety Information and Boxed Warning, please visit HEPZATOKIT.com. For more information regarding CHEMOSAT and its use, please visit Chemosat.com.

### **DYADIC INTERNATIONAL, INC. (NASDAQ: DYAI)**

**Dev. Pharma: Protein Production | Market Cap: \$45M**

Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical and bio-industrial products for human and animal health and alternative proteins.

### **ELSE NUTRITION HOLDINGS (OTCQX: BABYF / TSXV: BABY)**

**Consumer: Baby Food | Market Cap: \$26M**

Else Nutrition Holdings Inc. (TSX: BABY, OTCQX: BABYF, FSE: OYL) is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy formula is a clean-ingredient alternative to dairy-based formulas. Since launching its Plant-Based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of powerful testimonials and reviews from parents, gained national retailer support, and achieved rapid sales growth.

### **FLOW BEVERAGE CORP. (OTCQX: FLWBF / TSX: FLOW)**

**Consumer: Water | Market Cap: \$13M**

Flow is one of the fastest-growing premium water companies in North America. Founded in 2014, Flow's mission since day one has been to reduce environmental impacts by providing sustainably sourced naturally alkaline spring water in a recyclable and up to 75% renewable, plant-based pack. Today, the brand is B-Corp Certified with a best-in-class score of 126.5, offering a diversified line of health and wellness-oriented beverage products: original naturally alkaline spring water and award-winning organic flavours in sizes ranging from 330-ml to 1-litre. All products contain naturally occurring electrolytes and essential minerals and support Flow's overarching purpose to "bring wellness to the world through the positive power of water."

### **GREENFIRE RESOURCES (NYSE: GFR / TSX: GFR)**

**Basic Materials: Canadian Oil Sands | Market Cap: \$400M**

Greenfire is an intermediate, lower-cost and growth-oriented Athabasca oil sands producer with concentrated Tier-1 assets that use steam assisted gravity drainage extraction methods. The Company is focused on responsible and sustainable energy development in Canada, with its registered office located in Calgary, Alberta. Greenfire is an operationally focused company with an emphasis on an entrepreneurial environment and employee ownership. Greenfire common shares are listed on the New York Stock Exchange and Toronto Stock Exchange under the symbol "GFR".

## COMPANY PROFILES

Market Cap data (\$USD) updated as of 4.29.24

### **GSE SYSTEMS, INC. (NASDAQ: GVP)**

**Technology: Nuclear | Market Cap: \$10M**

Proven by more than 50 years of experience in the nuclear power industry, GSE knows what it takes to help customers deliver carbon-free electricity safely and reliably. Today, GSE Solutions leverages top talent, expertise, and technology to help energy facilities achieve next-level power plant performance. GSE's advanced Engineering and Workforce Solutions divisions offer highly specialized training, engineering design, program compliance, simulation, and technical staffing that reduce risk and optimize plant operations. With more than 1,100 installations and hundreds of customers in over 50 countries, GSE delivers operational excellence. [www.gses.com](http://www.gses.com).

### **IMMUCELL CORPORATION (NASDAQ: ICCG)**

**Healthcare: Animal Health | Market Cap: \$40M**

ImmuCell Corporation's (Nasdaq: ICCG) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows with a no milk discard claim that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: <http://www.immuell.com>.

### **INVO BIOSCIENCE (NASDAQ: INVO)**

**Healthcare: Fertility | Market Cap: \$4M**

INVO Bioscience is a healthcare services fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility care accessible and inclusive to people around the world. Our commercialization strategy is focused on the opening of dedicated "INVO Centers" offering the INVOcell® and IVC procedure (with three centers in North America now operational), the acquisition of US-based, profitable in vitro fertilization ("IVF") clinics and the sale and distribution of our technology solution into existing fertility clinics. Our proprietary technology, INVOcell®, is a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as "IVC", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination ("IUI"). For more information, please visit [www.invobio.com](http://www.invobio.com).

### **JAGUAR HEALTH (NASDAQ: JAGX)**

**Comm. Pharma: GI | Market Cap: \$47M**

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

### **KAIROS PHARMA (PRIVATE)**

**Dev. Pharma: Oncology**

Kairos Pharma, a clinical-stage biopharmaceutical company developing cancer therapeutics, aims to improve established standard of care drugs. Kairos is a Greek word meaning "the opportune moment." Therapeutics developed at Kairos seeks to intervene at the opportune moment that a cancer patient becomes resistant to a cancer drug. ENV 105 aims to reverse their resistance to the drug and allows the drug to become effective again. Cancer develops resistance to drugs and suppresses the immune system. Through the power of structural biology, Kairos has developed therapeutics that reverse cancer drug resistance and immune suppression.

### **KIORA PHARMA (NASDAQ: KPRX)**

**Dev. Pharma: Retinal Disease | Market Cap: \$32M**

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

### **LINCOLN EDUCATIONAL SERVICES (NASDAQ: LINC)**

**Consumer: Education Services | Market Cap: \$315M**

Lincoln Educational Services leads post secondary vocational school training for the transportation, skilled trades and healthcare fields.

### **LIQTECH INTERNATIONAL, INC. (NASDAQ: LIQT)**

**Industrials: Filtration | Market Cap: \$15M**

LiqTech International, Inc., a Nevada corporation, is a clean technology company that provides state-of-the-art ceramic silicon carbide filtration technologies for gas and liquid purification. LiqTech's silicon carbide membranes are designed to be used in the most challenging water purification applications, and its silicon carbide filters are used to control diesel exhaust soot emissions. Applying nanotechnology, LiqTech develops products using its proprietary silicon carbide technology, resulting in a wide range of component membranes, membrane systems, and filters for both microfiltration and ultrafiltration applications. By incorporating LiqTech's SiC liquid membrane technology with the Company's extensive systems design experience and capabilities, LiqTech offers unique, turnkey solutions for the most difficult water purification applications. For more information, please visit [www.liqtech.com](http://www.liqtech.com).



## COMPANY PROFILES

Market Cap data (\$USD) updated as of 4.29.24

### **LUCAS GC LIMITED (NASDAQ: LGCL)**

**Technology: Staffing Services | Market Cap: \$200M**

Lucas GC Limited is the largest AI technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China in terms of the number of active users in the human resources industry as of June 30, 2022 and total net revenues for the year ended December 31, 2021. As a company empowered by artificial intelligence, data analytics, and blockchain technologies, Lucas is committed to digitalizing and intellectualizing the entire human capital management process. Lucas provides a platform to support trusted private social networks of professionals, through which it provides services consisting of recruitment services, outsourcing services, and other services such as information technology services and training services. The Company's users are primarily professionals who work in human resources related functions. The Company's corporate customers are corporations with recruitment, training, sales leads generation and outsourcing demands. For more information, please visit: <https://www.lucasgchr.com/>.

### **MODULAR MEDICAL, INC. (NASDAQ: MODD)**

**Medical Device: Insulin Pump | Market Cap: \$47M**

Modular Medical, Inc. (Nasdaq:MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Commercialization of an innovative insulin pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, its MODD1 product, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that presently-available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, it seeks to expand the wearable insulin delivery device market beyond the highly motivated "super users" and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

### **MOGO INC. (NASDAQ: MOGO / TSX: MOGO)**

**Technology: FinTech | Market Cap: \$45M**

Mogo Inc. (NASDAQ:MOGO; TSX:MOGO) is a digital wealth and payments company headquartered in Vancouver, Canada with more than 2 million members, \$9.9B in annual payments volume and a ~13% equity stake in Canada's leading Crypto Exchange WonderFi (TSX:WNDR). Mogo offers simple digital solutions to help its members dramatically improve their path to wealth-creation and financial freedom. MOGO offers commission-free stock trading that helps users thoughtfully invest based on a Warren Buffett approach to long-term investing – while also making a positive impact with every investment. Moka offers Canadians a real alternative to mutual funds and wealth managers that overcharge and underperform with a fully managed investing solution based on the proven outperformance of an S&P 500 strategy, and at a fraction of the cost. Through its wholly owned digital payments subsidiary, Carta Worldwide, Mogo also offers a low-cost payments platform that powers next-generation card programs for companies across Europe and Canada. The Company, which was founded in 2003, has approximately 200 employees across its offices in Vancouver, Toronto, London & Casablanca.

### **NEURAXIS (NYSE AMERICAN: NRXS)**

**Medical Device: Irritable Bowel | Market Cap: \$20M**

NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit <http://neuraxis.com>.

### **PERASO INC. (NASDAQ: PRSO)**

**Technology: Semiconductors | Market Cap: \$4M**

Peraso Inc. (NASDAQ:PRSO) is a pioneer in high-performance 60 GHz unlicensed and 5G mmWave wireless technology, offering chipsets, antenna modules, software, and IP. Peraso supports a variety of applications, including fixed wireless access, immersive video, and factory automation. In addition, Peraso's solutions for data and telecom networks focus on Accelerating Data Intelligence and Multi-Access Edge Computing, providing end-to-end solutions from the edge to the centralized core and into the cloud. For additional information, please visit [www.perasoinc.com](http://www.perasoinc.com).

### **PRECISION OPTICS CORPORATION (NASDAQ: POCI)**

**Technology: Optics | Market Cap: \$35M**

Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Lighthouse Imaging division's electronic imaging expertise and its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company designs and manufactures next-generation product solutions to meet the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery, including single-use medical devices, as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies with a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit [www.poci.com](http://www.poci.com).

## COMPANY PROFILES

Market Cap data (\$USD) updated as of 4.29.24

### **RELIQ HEALTH TECHNOLOGIES (OTC: RQHTF / TSXV: RHT)**

**Healthcare: Technology Services | Market Cap: \$35M**

Reliq Health Technologies is a growing global healthcare technology company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq's powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the Frankfurt Stock Exchange under the WKN: A2AJTB.

### **REVIVA PHARMACEUTICALS HOLDINGS (NASDAQ: RVPH)**

**Dev. Pharma: CNS | Market Cap: \$83M**

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

### **SABIO HOLDINGS INC. (OTCQX: SABOF / TSXV: SBIO)**

**Technology: Advertising | Market Cap: \$12M**

Sabio Holdings (TSXV: SBIO, OTCQX: SABOF) is a technology and services leader in the fast-growing, ad-supported streaming space. Its cloud-based, end-to-end technology stack works with top blue-chip global brands and the agencies that represent them to reach, engage, and validate streaming audiences. Sabio Holdings' companies consist of Sabio – a demand-side platform (DSP) powered through our proprietary ad-serving technology; App Science™ – a non-cookie-based software as a service (SAAS) analytics and insights platform with AI natural language capabilities; and Vidillion – an ad-supported streaming supply-side platform (SSP) that includes server-side ad-insertion (SSAI) technology. For more information, visit: [sabioholding.com](http://sabioholding.com).

### **S&W SEED COMPANY (NASDAQ: SANW)**

**Industrials: Agriculture | Market Cap: \$20M**

Founded in 1980, S&W Seed Company is a global multi-crop, middle-market agricultural company headquartered in Longmont, Colorado. S&W's vision is to be the world's preferred proprietary seed company which supplies a range of sorghum, forage and specialty crop products that supports the growing global demand for animal proteins and healthier consumer diets. S&W is a global leader in proprietary alfalfa and sorghum seeds with significant research and development, production and distribution capabilities. S&W also has a commercial presence in pasture and sunflower seeds, and through a partnership, is focused on sustainable biofuel feedstocks primarily within camelina. For more information, please visit [www.swseedco.com](http://www.swseedco.com).

### **SCIENTIFIC INDUSTRIES, INC. (OTCQB: SCND)**

**Healthcare: Life Sciences | Market Cap: \$18M**

Scientific Industries (OTCQB:SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems under the product name Cell Growth Quantifier and Liquid Injection System. Scientific Industries' products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit [www.scientificindustries.com](http://www.scientificindustries.com). Scientific Bioprocessing, Inc. ("SBI") is dedicated to providing state-of-the-art instruments, strategies, and technologies to expedite the production of viable cells and therapies with a streamlined process and product consistency. SBI's mission is to develop sensor technologies and instruments that make cell culture and bioprocessing work easier, experiments more reproducible, and culture conditions better suited to meet experimental objectives. SBI is a subsidiary of Scientific Industries Holdings, Inc. To learn more, visit [www.scientificbio.com](http://www.scientificbio.com).

### **SENESTECH (NASDAQ: SNES)**

**Industrials: Rodent Control | Market Cap: \$5M**

We are committed to improving the health of the world by humanely managing animal pest populations, applying our expertise in fertility control. We invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, and Evolve, an EPA-designated minimum-risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. We strive for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable. For more information visit <https://senestech.com/> and <https://contrapeststore.com>.

### **SHUTTLE PHARMACEUTICALS, INC. (NASDAQ: SHPH)**

**Dev. Pharma: Oncology | Market Cap: \$7M**

Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at [www.shuttlepharma.com](http://www.shuttlepharma.com).



## COMPANY PROFILES

Market Cap data (\$USD) updated as of 4.29.24

### **SOBR SAFE, INC. (NASDAQ: SOBR)**

**Technology: Alcohol Detection | Market Cap: \$6M**

SOBR Safe provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. These technologies are integrated within a robust and scalable data platform, producing statistical and measurable user and business data. Its mission is to save lives, increase productivity, create significant economic benefits and positively impact behavior.

### **SPIRE GLOBAL (NYSE: SPIR)**

**Technology: Satellite | Market Cap: \$237M**

Spire (NYSE: SPIR) is a global provider of space-based data, analytics and space services, offering unique datasets and powerful insights about Earth so that organizations can make decisions with confidence in a rapidly changing world. Spire builds, owns, and operates a fully deployed satellite constellation that observes the Earth in real time using radio frequency technology. The data acquired by Spire's satellites provides global weather intelligence, ship and plane movements, and spoofing and jamming detection to better predict how their patterns impact economies, global security, business operations, and the environment. Spire also offers Space as a Service solutions that empower customers to leverage its established infrastructure to put their business in space. Spire has nine offices across the U.S., Canada, UK, Luxembourg, Germany and Singapore.

### **SYRA HEALTH CORP. (NASDAQ: SYRA)**

**Healthcare: Behavioral Technology | Market Cap: \$15M**

Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit [www.syrahealth.com](http://www.syrahealth.com).

### **THE GLIMPSE GROUP (NASDAQ: VRAR)**

**Technology: VR/AR Software | Market Cap: \$20M**

The Glimpse Group (NASDAQ:VRAR),(FSE:9DR) is a diversified Immersive technology platform company, providing enterprise-focused Virtual Reality, Augmented Reality and Spatial Computing software & services. Glimpse's unique business model builds scale and a robust ecosystem, while simultaneously providing investors an opportunity to invest directly into this emerging industry via a diversified platform. For more information on The Glimpse Group, please visit [www.theglimpsegroup.com](http://www.theglimpsegroup.com)

### **TRINITY BIOTECH PLC (NASDAQ: TRIB)**

**Healthcare: Diagnostics | Market Cap: \$18M**

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: [www.trinitybiotech.com](http://www.trinitybiotech.com).

### **UNICYCIVE THERAPEUTICS, INC. (NASDAQ: UNCY)**

**Dev. Pharma: Kidney Disease | Market Cap: \$35M**

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in Phase 1 clinical trial for the treatment of acute kidney injury.

### **ZOMEDICA (NYSE AMERICAN: ZOM)**

**Medical Device: Animal Health | Market Cap: \$128M**

Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit [www.zomedica.com](http://www.zomedica.com).

### **ZOOMD TECHNOLOGIES (OTC: ZMDTF / TSXV: ZOMD)**

**Technology: Advertising | Market Cap: \$6M**

Zoomd (TSXV: ZOMD, OTC: ZMDTF), founded in 2012 and began trading on the TSX Venture Exchange in September 2019, offers a site search engine to publishers, and a mobile app user-acquisition platform, integrated with a majority of global digital media, to advertisers. The platform unifies more than 600 media sources into one unified dashboard offering advertisers a user acquisition control center for managing all new customer acquisition campaigns using a single platform. By unifying all these media sources onto a single platform, Zoomd saves advertisers significant resources that would otherwise be spent consolidating data sources, thereby maximizing data collection and data insights while minimizing the resources spent on the exercise. Further, Zoomd is a performance-based platform that allows advertisers to advertise to the relevant target audiences using a key performance indicator-algorithm that is focused on achieving the advertisers' goals and targets.



## DISCLAIMERS / DISCLOSURES

Services: Lytham Partners, LLC ("Lytham") provides a range of investor relations services to its clients. The particular services provided vary by client and may change from time to time. Compensation Information: Lytham is compensated by its clients for providing investor relations services. Click here for full compensation information: <https://lythampartners.com/disclosures/>. No Investment Advice: Lytham is not a registered broker-dealer, registered investment adviser or financial adviser, nor does it hold itself out to be. All materials presented on Lytham's website and/or publications or presentations released by Lytham to the public through its website, email, or any other means of transmission are not to be regarded as investment advice, do not constitute an endorsement of the company, and are only for informative purposes. Before making a purchase or sale of any securities mentioned in Lytham's publications or presentations or on its website, Lytham strongly encourages and recommends consultation with a registered securities representative. Lytham's website and/or publications or presentations released by Lytham to the public through its website, email, or any other means of transmission do not constitute an offer to purchase or sell securities, and is not to be construed as a representation of an offer or a solicitation of any offer by Lytham or its client companies to purchase or sell any security. Lytham or any of its affiliates, members, employees, clients, officers, directors, and/or their respective families may from time to time purchase or sell, as agents or principals, or otherwise hold positions in, securities of its client companies, and are free to buy or sell those positions at will. Any such positions may be increased or decreased from time to time in the future without notice. Any information or opinions expressed on Lytham's website and/or publications or presentations released by Lytham are subject to change without notice. Lytham's full disclaimer/disclosures statement can be found on its website at <https://lythampartners.com/disclosures/>.

